Effects of epigenetic-based anti-cancer drugs in leukaemia and multiple myeloma cells

被引:8
|
作者
Jugova, Alzbeta [1 ]
Sustackova, Gabriela [1 ]
Legartova, Sona [1 ]
Stixova, Lenka [1 ]
Kozubek, Stanislav [1 ]
Bartova, Eva [1 ]
机构
[1] Acad Sci Czech Republ, Inst Biophys, Vvi, CZ-61265 Brno, Czech Republic
关键词
epigenetics; histone code; leukaemia cells; multiple myeloma (MM); GENE-EXPRESSION; DNA METHYLATION; HP1; PROTEINS; CANCER; HETEROCHROMATIN; HP1(HS-ALPHA); INHIBITION; RECEPTOR; TARGETS;
D O I
10.1042/CBI20100820
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Here, we focus on epigenetic changes in leukaemia and MM (multiple myeloma) cells. We show how the histone signature, DNA methylation and levels of select tumour-suppressor proteins can be affected by inhibitors of HDACs (histone deacetylases) and Dnmts (DNA methyltransferases). Both inhibitors, TSA (trichostatin A) and 5-AZA (5-azacytidine), have the ability to change the histone signature in a tumour-specific manner. In MM cells, we observed changes in H3K4 methylation, while in leukaemia cells, H3K9 methylation was especially affected by select inhibitors. Compared with normal peripheral blood lymphocytes, tumour cell samples were characterized by increased H3K9 acetylation, increased H3K4me2, H3K9me2 and HP1 alpha (heterochromatin protein 1 alpha) levels and specific changes were also observed for DNA methylation. Additionally, we showed that the tumour suppressor pRb1 (retinoblastoma protein) is more sensitive to epigenetic-based anti-cancer stimuli than p53. We have found significant decrease in the levels of pRbl and p53 in both myeloma and leukaemia cells after HDAC inhibition.
引用
收藏
页码:1195 / 1203
页数:9
相关论文
共 50 条
  • [21] Development of Anti-cancer Drugs
    Arrondeau, Jennifer
    Gan, Hui K.
    Razak, Albiruni R. A.
    Paoletti, Xavier
    Le Tourneau, Christophe
    DISCOVERY MEDICINE, 2010, 10 (53) : 355 - 362
  • [22] HANDLING ANTI-CANCER DRUGS
    不详
    LANCET, 1983, 1 (8323): : 543 - 543
  • [23] TESTING ANTI-CANCER DRUGS
    不详
    LANCET, 1972, 1 (7755): : 827 - +
  • [24] Anti-cancer drugs for cardioprotection
    Wu, Nan
    Xie, Yizhen
    Yang, Burton B.
    CELL CYCLE, 2017, 16 (02) : 155 - 156
  • [25] TESTING ANTI-CANCER DRUGS
    BERENBAUM, MC
    SHEARD, CE
    LANCET, 1972, 1 (7760): : 1116 - +
  • [26] Improved anti-cancer drugs
    Barden, D
    DALTON TRANSACTIONS, 2005, (11) : C42 - C42
  • [27] Improved anti-cancer drugs
    Barden, D
    CHEMISTRY WORLD, 2005, 2 (06): : 20 - 20
  • [28] TESTING ANTI-CANCER DRUGS
    MITCHELL, JS
    DAWSON, MPA
    DENDY, PP
    WHEELER, TK
    LANCET, 1972, 1 (7757): : 955 - &
  • [29] Proteomics of anti-cancer drugs
    Kovarova, H.
    Martinkova, J.
    Hrabakova, R.
    Skalnikova, H.
    Novak, P.
    Hajduch, M.
    Gadher, S. J.
    FEBS JOURNAL, 2009, 276 : 84 - 84
  • [30] Application to anti-cancer drugs
    Olejniczak, K.
    TOXICOLOGY LETTERS, 2011, 205 : S2 - S2